FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108758562> ?p ?o ?g. }

• W2108758562 endingPage "1844" @default.
• W2108758562 startingPage "1836" @default.
• W2108758562 abstract "In situ gene therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF) was demonstrated to successfully inhibit tumour cell growth in a mouse orthotopic bladder cancer model, but suffered from several disadvantages, such as limited efficiency for gene delivery, low expression efficiency of the transgene and the safety concern resulting from viral vector. In order to address the limits, a novel immunotherapy was developed attentively through immobilization of streptavidin-tagged bioactive GM-CSF on the biotinylated mucosal surface of bladder wall on the basis of both the unique property of streptavidin (SA) to bind rapidly and almost irreversibly to any biotin-linked molecule and the outstanding ability of biotin to be incorporated easily into the proteins on the cell surface. The mouse orthotopic model of MB49 bladder cancer was used to evaluate the feasibility and efficacy of the novel immunotherapy performed twice a week for 3 weeks. Briefly, 1 day after intravesical implantation of 1 x 10(6) MB49 tumour cells in C57BL/6 mouse, 100 microl of 1 mg/ml NHS-PEO4-biotin was instilled and allowed to incubate in the bladder for 30 min., followed by intravesical instillation of 100 microl of 0.15 mg/ml SA-GM-CSF bifunctional fusion protein and incubation for 1 hr. SA-GM-CSF fusion protein was shown to be immobilized efficiently and durably on the biotinylated mucosal surface of bladder wall. The bladder cancer incidence was dramatically decreased from 100% in the control group to 37.5% in the SA-GM-CSF group. Importantly, 70% of the SA-GM-CSF-cured mice were protected against a second intravesical wild-type MB49 tumour challenge, indicating that an effective anti-tumour immunity was generated against MB49 bladder cancer. Thus, the novel immunotherapy may be an attractive therapeutic alternative and should be evaluated in bladder cancer patients." @default.
• W2108758562 created "2016-06-24" @default.
• W2108758562 creator A5004143556 @default.
• W2108758562 creator A5005820169 @default.
• W2108758562 creator A5024986601 @default.
• W2108758562 creator A5034373413 @default.
• W2108758562 creator A5043632234 @default.
• W2108758562 creator A5066931842 @default.
• W2108758562 creator A5078213280 @default.
• W2108758562 creator A5088772562 @default.
• W2108758562 date "2009-07-20" @default.
• W2108758562 modified "2023-09-26" @default.
• W2108758562 title "A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF" @default.
• W2108758562 cites W1504459554 @default.
• W2108758562 cites W1891586069 @default.
• W2108758562 cites W1974721233 @default.
• W2108758562 cites W1983596254 @default.
• W2108758562 cites W1990144050 @default.
• W2108758562 cites W2021396643 @default.
• W2108758562 cites W2037886909 @default.
• W2108758562 cites W2051782273 @default.
• W2108758562 cites W2056173512 @default.
• W2108758562 cites W2062872356 @default.
• W2108758562 cites W2080633739 @default.
• W2108758562 cites W2094819753 @default.
• W2108758562 cites W2101706701 @default.
• W2108758562 cites W2105725802 @default.
• W2108758562 cites W2132951532 @default.
• W2108758562 cites W2258595633 @default.
• W2108758562 cites W4256417123 @default.
• W2108758562 doi "https://doi.org/10.1111/j.1582-4934.2009.00818.x" @default.
• W2108758562 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3829043" @default.
• W2108758562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19627402" @default.
• W2108758562 hasPublicationYear "2009" @default.
• W2108758562 type Work @default.
• W2108758562 sameAs 2108758562 @default.
• W2108758562 citedByCount "18" @default.
• W2108758562 countsByYear W21087585622012 @default.
• W2108758562 countsByYear W21087585622013 @default.
• W2108758562 countsByYear W21087585622014 @default.
• W2108758562 countsByYear W21087585622015 @default.
• W2108758562 countsByYear W21087585622016 @default.
• W2108758562 countsByYear W21087585622017 @default.
• W2108758562 countsByYear W21087585622018 @default.
• W2108758562 countsByYear W21087585622019 @default.
• W2108758562 countsByYear W21087585622021 @default.
• W2108758562 countsByYear W21087585622022 @default.
• W2108758562 countsByYear W21087585622023 @default.
• W2108758562 crossrefType "journal-article" @default.
• W2108758562 hasAuthorship W2108758562A5004143556 @default.
• W2108758562 hasAuthorship W2108758562A5005820169 @default.
• W2108758562 hasAuthorship W2108758562A5024986601 @default.
• W2108758562 hasAuthorship W2108758562A5034373413 @default.
• W2108758562 hasAuthorship W2108758562A5043632234 @default.
• W2108758562 hasAuthorship W2108758562A5066931842 @default.
• W2108758562 hasAuthorship W2108758562A5078213280 @default.
• W2108758562 hasAuthorship W2108758562A5088772562 @default.
• W2108758562 hasBestOaLocation W21087585621 @default.
• W2108758562 hasConcept C104317684 @default.
• W2108758562 hasConcept C111599444 @default.
• W2108758562 hasConcept C121608353 @default.
• W2108758562 hasConcept C126322002 @default.
• W2108758562 hasConcept C142724271 @default.
• W2108758562 hasConcept C1491633281 @default.
• W2108758562 hasConcept C153911025 @default.
• W2108758562 hasConcept C185592680 @default.
• W2108758562 hasConcept C204628709 @default.
• W2108758562 hasConcept C2776190903 @default.
• W2108758562 hasConcept C2777701055 @default.
• W2108758562 hasConcept C2778204606 @default.
• W2108758562 hasConcept C2780352672 @default.
• W2108758562 hasConcept C2780674031 @default.
• W2108758562 hasConcept C502942594 @default.
• W2108758562 hasConcept C55493867 @default.
• W2108758562 hasConcept C71924100 @default.
• W2108758562 hasConcept C86803240 @default.
• W2108758562 hasConceptScore W2108758562C104317684 @default.
• W2108758562 hasConceptScore W2108758562C111599444 @default.
• W2108758562 hasConceptScore W2108758562C121608353 @default.
• W2108758562 hasConceptScore W2108758562C126322002 @default.
• W2108758562 hasConceptScore W2108758562C142724271 @default.
• W2108758562 hasConceptScore W2108758562C1491633281 @default.
• W2108758562 hasConceptScore W2108758562C153911025 @default.
• W2108758562 hasConceptScore W2108758562C185592680 @default.
• W2108758562 hasConceptScore W2108758562C204628709 @default.
• W2108758562 hasConceptScore W2108758562C2776190903 @default.
• W2108758562 hasConceptScore W2108758562C2777701055 @default.
• W2108758562 hasConceptScore W2108758562C2778204606 @default.
• W2108758562 hasConceptScore W2108758562C2780352672 @default.
• W2108758562 hasConceptScore W2108758562C2780674031 @default.
• W2108758562 hasConceptScore W2108758562C502942594 @default.
• W2108758562 hasConceptScore W2108758562C55493867 @default.
• W2108758562 hasConceptScore W2108758562C71924100 @default.
• W2108758562 hasConceptScore W2108758562C86803240 @default.
• W2108758562 hasIssue "6b" @default.
• W2108758562 hasLocation W21087585621 @default.
• W2108758562 hasLocation W21087585622 @default.
• W2108758562 hasLocation W21087585623 @default.

• next